Summary
58 / 100 · Bulios Score
What speaks for it
- The share price is below the Bulios Fair Price.
- It has been profitable 6 years in a row.
What to watch
- Earnings per share fell by 5.8% a year over the last 3 years.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 12.6 THB for 1 THB of yearly profit.
Valuation in detailIs it growing?
It is shrinkingRevenue (THB)
Diluted EPS (THB)
- Analyst estimate
Revenue grew by 14% a year over 5 years. Over the last 3 years it grew by 6.6% a year. Earnings per share fell by 5.8% a year over the last 3 years.
Growth in detailDoes it make money?
ReasonablyWhere 100 THB of revenue goes
- Cost of sales 79 THB
- Sales and administration 11 THB
- Taxes and other 2.8 THB
- Net profit 7.6 THB
Net profit, industry median (Medical - Instruments & Supplies) 8.4 THB
Out of every 100 THB of revenue, 7.6 THB is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 10.0 years of free cash flow. Its debt is larger than its cash. The debt score is high even so.
Financial health in detailDoes it pay a dividend?
Small, at risk- Yield
- 2.13%
- Paid out of profit
- 27%
You receive ฿0.15 per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detail